Brewer G J, Johnson V, Kaplan J
University of Michigan Medical School, Ann Arbor 48109-0618, USA.
J Lab Clin Med. 1997 Jun;129(6):649-52. doi: 10.1016/s0022-2143(97)90200-6.
Although administration of zinc to human subjects has been reported to interfere with lymphocyte function, this single report has never been confirmed or refuted. We have developed zinc as a lifelong therapy for patients with Wilson's disease. Interference with lymphocyte function occurring as a side effect of zinc therapy could produce serious problems in our patients. We evaluated lymphocyte mitogenic response and natural killer cell activity in patients with Wilson's disease treated for 5 years or longer with zinc, in comparison with normal controls, and found no differences. In a second study, we evaluated these same parameters in patients with Wilson's disease before and after 1 year of zinc therapy, and again found no significant differences. We have seen no indications of immune suppression or increased susceptibility to infections in our patients, who have now been treated with zinc for up to 15 years. We conclude that any side effects from compromised lymphocyte function caused by administration of zinc are not of concern to patients with Wilson's disease.
尽管有报告称给人体受试者服用锌会干扰淋巴细胞功能，但这一单一报告从未得到证实或反驳。我们已将锌开发为威尔逊氏病患者的终身治疗方法。锌治疗的副作用导致淋巴细胞功能受到干扰，这可能会给我们的患者带来严重问题。我们评估了接受锌治疗5年或更长时间的威尔逊氏病患者的淋巴细胞有丝分裂反应和自然杀伤细胞活性，并与正常对照组进行比较，未发现差异。在第二项研究中，我们评估了威尔逊氏病患者在锌治疗1年前后的这些相同参数，同样未发现显著差异。我们的患者现已接受锌治疗长达15年，未发现免疫抑制或感染易感性增加的迹象。我们得出结论，锌给药导致的淋巴细胞功能受损所产生的任何副作用，对于威尔逊氏病患者而言并不值得担忧。
